Journal of Experimental & Clinical Medicine
Volume 2, Issue 4 , Pages 145-155, August 2010

The Role of Mitochondria in HIV Infection and Its Treatment

Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy

Received 7 April 2010; received in revised form 5 June 2010; accepted 9 June 2010.

Article Outline

Mitochondria play a dual role in the life of the cell, being capable of producing either energy (in the form of ATP) or potentially dangerous reactive oxygen species (ROS), and they also contain molecules that, when released into the cytoplasm, cause apoptosis. There is a growing interest in the importance of these organelles during the infection caused by the human immunodeficiency virus (HIV), as well as during its treatment. Indeed, several drugs that are capable of blocking HIV can also interact with the enzyme responsible for the replication of mitochondrial DNA and inhibit its activity. Cytokines produced by the immune system can alter ROS production. Furthermore, the virus as such can trigger different mechanisms that interfere with mitochondrial functionality and induce alterations, ultimately causing cell death. As a result, mitochondria can be severely altered by HIV infection and by its treatment.

Key Words:  AIDS , antiretroviral therapy , HAART , HIV , mitochondria , mitochondrial DNA

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Taylor SW, Fahy E, Zhang B, Glenn GM, Warnock DE, Wiley S, et al  Characterization of the human heart mitochondrial proteome . Nat Biotechnol . 2003;21:281–286
  2. Wallace DC . The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement . Gene . 2005;354:169–180
  3. Kujoth GC , Bradshaw PC , Haroon S , Prolla TA . The role of mitochondrial DNA mutations in mammalian aging . PLoS Genet . 2007;3:e24
  4. Pedersen PL . The cancer cell's “power plants” as promising therapeutic targets: an overview . J Bioenerg Biomembr . 2007;39:1–12
  5. Reichert AS , Neupert W . Mitochondriomics or what makes us breathe . Trends Genet . 2004;20:555–562
  6. Kroemer G , Galluzzi L , Brenner C . Mitochondrial membrane permeabilization in cell death . Physiol Rev . 2007;87:99–163
  7. Barbieri D, Abbracchio MP, Salvioli S, Monti D, Cossarizza A, Ceruti S, et al  Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells . Neurochem Int . 1998;32:493–504
  8. Ceruti S, Barbieri D, Veronese E, Cattabeni F, Cossarizza A, Giammarioli AM, et al  Different pathways of apoptosis revealed by 2-chloro-adenosine and deoxy-D-ribose in mammalian astroglial cells . J Neurosci Res . 1997;47:372–383
  9. Salvioli S, Dobrucki J, Moretti L, Troiano L, Fernandez MG, Pinti M, et al  Mitochondrial heterogeneity during staurosporine-induced apoptosis in HL60 cells: analysis at the single cell and single organelle level . Cytometry . 2000;40:189–197
  10. Garrido C , Galluzzi L , Brunet M , Puig PE , Didelot C , Kroemer G . Mechanisms of cytochrome c release from mitochondria . Cell Death Differ . 2006;13:1423–1433
  11. Galluzzi L , Larochette N , Zamzami N , Kroemer G . Mitochondria as therapeutic targets for cancer chemotherapy . Oncogene . 2006;25:4812–4830
  12. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, et al  3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro . Proc Natl Acad Sci USA . 1985;82:7096–7100
  13. Ho DD , Neumann AU , Perelson AS , Chen W , Leonard JM , Markowitz M . Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection . Nature . 1995;373:123–126
  14. Perelson AS , Essunger P , Ho DD . Dynamics of HIV-1 and CD4 + lymphocytes in vivo . AIDS . 1997;11(Suppl A):S17–S24
  15. Ho DD . Time to hit HIV, early and hard . N Engl J Med . 1995;333:450–451
  16. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators . N Engl J Med . 1998;338:853–860
  17. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al  Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease . Science . 1997;277:112–116
  18. Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, et al  Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study . J Infect Dis . 2000;181:1635–1642
  19. Mussini C, Pezzotti P, Miro JM, Martinez E, de Quiros JC, Cinque P, et al  Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study . Clin Infect Dis . 2004;38:565–571
  20. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry . Nat Med . 1998;4:1302–1307
  21. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al  Efficacy of shortterm monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 . Nat Med . 2005;11:1170–1172
  22. Hicks C , Gulick RM . Raltegravir: the first HIV type 1 integrase inhibitor . Clin Infect Dis . 2009;48:931–939
  23. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al  Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase . Proc Natl Acad Sci USA . 1986;83:8333–8337
  24. Lynx MD , McKee EE . 3′-Azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria . Biochem Pharmacol . 2006;72:239–243
  25. Lynx MD , Bentley AT , McKee EE . 3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity . Biochem Pharmacol . 2006;71:1342–1348
  26. Johnson MA , Fridland A . Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells . Mol Pharmacol . 1989;36:291–295
  27. Benbrik E, Chariot P, Bonavaud S, Ammi-Said M, Frisdal E, Rey C, et al  Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells . J Neurol Sci . 1997;149:19–25
  28. Setzer B , Schlesier M , Walker UA . Effects of of didanosine-related depletion of mtDNA in human T lymphocytes . J Infect Dis . 2005;191:848–855
  29. Balzarini J, Cooney DA, Dalal M, Kang GJ, Cupp JE, DeClercq E, et al  2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis . Mol Pharmacol . 1987;32:798–806
  30. Lee H , Hanes J , Johnson KA . Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase . Biochemistry . 2003;42:14711–14719
  31. Becher F, Landman R, Mboup S, Kane CN, Canestri A, Liegeois F, et al  Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients . AIDS . 2004;18:181–187
  32. Ho HT , Hitchcock MJ . Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus . Antimicrob Agents Chemother . 1989;33:844–849
  33. Gerschenson M, Nguyen VT, St Claire MC, Harbaugh SW, Harbaugh JW, Proia LA, et al. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys . J Hum Virol . 2001;4:335–342
  34. Gaou I, Malliti M, Guimont MC, Letteron P, Demeilliers C, Peytavin G, et al  Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice . J Pharmacol Exp Ther . 2001;297:516–523
  35. Velsor LW , Kovacevic M , Goldstein M , Leitner HM , Lewis W , Day BJ . Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine . Toxicol Appl Pharmacol . 2004;199:10–19
  36. Pinti M, Gibellini L, Guaraldi G, Orlando G, Gant TW, Morselli E, et al  Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipo-dystrophy: implications for the pathogenesis of the disease . AIDS . 2010;24:841–850
  37. Shewach DS , Liotta DC , Schinazi RF . Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase . Biochem Pharmacol . 1993;45:1540–1543
  38. Cui L, Schinazi RF, Gosselin G, Imbach JL, Chu CK, Rando RF, et al  Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity . Biochem Pharmacol . 1996;52:1577–1584
  39. Venhoff N , Setzer B , Melkaoui K , Walker UA . Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors . Antivir Ther . 2007;12:1075–1085
  40. Harris M , Back D , Kewn S , Jutha S , Marina R , Montaner JS . Intracellular carbovir triphosphate levels in patients taking abacavir once a day . AIDS . 2002;16:1196–1197
  41. Hawkins T , Veikley W , St Claire RL , Guyer B , Clark N , Kearney BP . Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens . J Acquir Immune Defic Syndr . 2005;39:406–411
  42. Faletto MB , Miller WH , Garvey EP , St Clair MH , Daluge SM , Good SS . Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 . Antimicrob Agents Chemother . 1997;41:1099–1107
  43. Rylova SN , Mirzaee S , Albertioni F , Eriksson S . Expression of deoxynucleoside kinases and 5′-nucleotidases in mouse tissues: implications for mitochondrial toxicity . Biochem Pharmacol . 2007;74:169–175
  44. Govindarajan R , Leung GP , Zhou M , Tse CM , Wang J , Unadkat JD . Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3 . Am J Physiol Gastrointest Liver Physiol . 2009;296:G910–G922
  45. Leung GP , Tse CM . The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity . Expert Opin Drug Metab Toxicol . 2007;3:705–718
  46. Lai Y , Tse CM , Unadkat JD . Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs . J Biol Chem . 2004;279:4490–4497
  47. Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J, et al. Direct analysis of mitochondrial toxicity of antiretroviral drugs . AIDS . 2001;15:1687–1694
  48. Cossarizza A, Pinti M, Moretti L, Bricalli D, Bianchi R, Troiano L, et al  Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active anti-retroviral therapy-related lipodystrophy . J Infect Dis . 2002;185:299–305
  49. Walker UA , Setzer B , Venhoff N . Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors . AIDS . 2002;16:2165–2173
  50. McComsey G , Tan DJ , Lederman M , Wilson E , Wong LJ . Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy . AIDS . 2002;16:513–518
  51. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, et al  Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients . J Acquir Immune Defic Syndr . 2002;29:117–121
  52. Miro O, Lopez S, Pedrol E, Rodriguez-Santiago B, Martinez E, Soler A, et al  Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy . Antivir Ther . 2003;8:333–338
  53. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients . N Engl J Med . 2002;346:811–820
  54. Lopez S, Miro O, Martinez E, Pedrol E, Rodriguez-Santiago B, Milinkovic A, et al  Mitochondrial effects of antiretroviral therapies in asymptomatic patients . Antivir Ther . 2004;9:47–55
  55. Maggiolo F, Roat E, Pinti M, Nasi M, Gibellini L, De Biasi S, et al  Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients . Antivir Ther . 2010;15:51–59
  56. Lim SE , Copeland WC . Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma . J Biol Chem . 2001;276:23616–23623
  57. Dalakas MC , Illa I , Pezeshkpour GH , Laukaitis JP , Cohen B , Griffin JL . Mitochondrial myopathy caused by long-term zidovudine therapy . N Engl J Med . 1990;322:1098–1105
  58. Lewis W, Papoian T, Gonzalez B, Louie H, Kelly DP, Payne RM, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts . Lab Invest . 1991;65:228–236
  59. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al  Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion . J Hepatol . 1999;30:156–160
  60. Kaguni LS . DNA polymerase gamma, the mitochondrial replicase . Annu Rev Biochem . 2004;73:293–320
  61. Lewis W , Day BJ , Copeland WC . Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective . Nat Rev Drug Discov . 2003;2:812–822
  62. Song S , Pursell ZF , Copeland WC , Longley MJ , Kunkel TA , Mathews CK . DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity . Proc Natl Acad Sci USA . 2005;102:4990–4995
  63. Chiappini F , Teicher E , Saffroy R , Debuire B , Vittecoq D , Lemoine A . Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study . Curr HIV Res . 2009;7:244–253
  64. Riddler SA , Anderson RE , Mellors JW . Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T) . Antiviral Res . 1995;27:189–203
  65. Rana KZ , Dudley MN . Clinical pharmacokinetics of stavudine . Clin Pharmacokinet . 1997;33:276–284
  66. Villalba N , Soriano V , Gomez-Cano M , Castilla J , Mas A , Gonzalez-Lahoz J . Short-term efficacy and safety of stavudine in pre-treated HIV-infected patients . Antivir Ther . 1997;2:185–189
  67. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda . Trans R Soc Trop Med Hyg . 2007;101:793–798
  68. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial . AIDS . 2002;16:2447–2454
  69. Lowe SH , Hassink EA , van Eck-Smit BL , Borleffs JC , Lange JM , Reiss P . Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES) . HIV Clin Trials . 2007;8:337–344
  70. ter Hofstede HJ , Koopmans PP , Burger DM . Stavudine plasma concentrations and lipoatrophy . J Antimicrob Chemother . 2008;61:933–938
  71. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy . AIDS . 2001;15:1801–1809
  72. McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, Ganz J, et al  Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection . Antivir Ther . 2008;13:715–722
  73. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, et al  Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine . AIDS . 2005;19:15–23
  74. Ribera E, Paradineiro JC, Curran A, Sauleda S, Garcia-Arumi E, Castella E, et al  Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study) . HIV Clin Trials . 2008;9:407–417
  75. Pedrol E, Masanes F, Fernandez-Sola J, Cofan M, Casademont J, Grau JM, et al. A lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies . J Neurol Sci . 1996;138:42–48
  76. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sanchez de la Rosa R, et al  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells . Antimicrob Agents Chemother . 2006;50:3824–3832
  77. Lonergan JT , Barber RE , Mathews WC . Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis . AIDS . 2003;17:2495–2499
  78. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al  Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial . JAMA . 2002;288:207–215
  79. Birkus G , Hitchcock MJ , Cihlar T . Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors . Antimicrob Agents Chemother . 2002;46:716–723
  80. Wensing AM , van Maarseveen NM , Nijhuis M . Fifteen years of HIV protease inhibitors: raising the barrier to resistance . Antiviral Res . 2010;85:59–74
  81. Badley AD . In vitro and in vivo effects of HIV protease inhibitors on apoptosis . Cell Death Differ . 2005;12(Suppl 1):924–931
  82. Weichold FF , Bryant JL , Pati S , Barabitskaya O , Gallo RC , Reitz MS . HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells . J Hum Virol . 1999;2:261–269
  83. Sloand EM , Young NS , Sato T , Kim S , Maciejewski JP . Inhibition of interleukin-1beta-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential . Exp Hematol . 1998;26:1093–1099
  84. Phenix BN , Lum JJ , Nie Z , Sanchez-Dardon J , Badley AD . Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss . Blood . 2001;98:1078–1085
  85. Sloand EM , Kumar PN , Kim S , Chaudhuri A , Weichold FF , Young NS . Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo . Blood . 1999;94:1021–1027
  86. Chavan S , Kodoth S , Pahwa R , Pahwa S . The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals . Blood . 2001;98:383–389
  87. Ghibelli L, Mengoni F, Lichtner M, Coppola S, De Nicola M, Bergamaschi A, et al  Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain . Biochem Pharmacol . 2003;66:1505–1512
  88. Cuerrier D , Nie Z , Badley AD , Davies PL . Ritonavir does not inhibit calpain in vitro . Biochem Biophys Res Commun . 2005;327:208–211
  89. Vanderklish PW , Bahr BA . The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states . Int J Exp Pathol . 2000;81:323–339
  90. Matarrese P , Gambardella L , Cassone A , Vella S , Cauda R , Malorni W . Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors . J Immunol . 2003;170:6006–6015
  91. Matarrese P, Tinari A, Gambardella L, Mormone E, Narilli P, Pierdominici M, et al  HIV protease inhibitors prevent mitochondrial hyperpolarization and redox imbalance and decrease endogenous uncoupler protein-2 expression in gp 120-activated human T lymphocytes . Antivir Ther . 2005;10(Suppl 2):M29–M45
  92. Miro O, Villarroya J, Garrabou G, Lopez S, Rodriguez de la Concepcion M, Pedrol E, et al  In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis . Antivir Ther . 2005;10:945–951
  93. Hisatomi T, Nakazawa T, Noda K, Almulki L, Miyahara S, Nakao S, et al  HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice . J Clin Invest . 2008;118:2025–2038
  94. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors . AIDS . 1998;12:F51–F58
  95. Samaras K , Wand H , Law M , Emery S , Cooper D , Carr A . Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using Interna tional Diabetes Foun dation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia . Diabetes Care . 2007;30:113–119 Erratum in: Diabetes Care . 2007;30:455
  96. Barbaro G , Iacobellis G . Metabolic syndrome associated with HIV and highly active antiretroviral therapy . Curr Diab Rep . 2009;9:37–42
  97. Grinspoon S , Carr A . Cardiovascular risk and body-fat abnormalities in HIV-infected adults . N Engl J Med . 2005;352:48–62
  98. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al  Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection . AIDS . 2007;21:2445–2453
  99. Carr A , Samaras K , Thorisdottir A , Kaufmann GR , Chisholm DJ , Cooper DA . Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study . Lancet . 1999;353:2093–2099
  100. Carr A , Miller J , Law M , Cooper DA . A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome . AIDS . 2000;14:F25–F32
  101. Carr A , Cooper DA . Adverse effects of antiretroviral therapy . Lancet . 2000;356:1423–1430
  102. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, et al  Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy . J Acquir Immune Defic Syndr . 2003;32:370–374
  103. Cossarizza A, Riva A, Pinti M, Ammannato S, Fedeli P, Mussini C, et al  Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy . Antivir Ther . 2003;8:315–321
  104. Calmy A , Hirschel B , Cooper DA , Carr A . A new era of antiretroviral drug toxicity . Antivir Ther . 2009;14:165–179
  105. Ladha JS , Tripathy MK , Mitra D . Mitochondrial complex I activity is impaired during HIV-1-induced T-cell apoptosis . Cell Death Differ . 2005;12:1417–1428
  106. Maagaard A , Holberg-Petersen M , Kvittingen EA , Sandvik L , Bruun JN . Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients . HIV Med . 2006;7:53–58
  107. Miura T, Goto M, Hosoya N, Odawara T, Kitamura Y, Nakamura T, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy . J Med Virol . 2003;70:497–505
  108. Prakash O, Teng S, Ali M, Zhu X, Coleman R, Dabdoub RA, et al  The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice . Arch Biochem Biophys . 1997;343:173–180
  109. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis . J Exp Med . 1992;176:1099–1106
  110. Groux H , Torpier G , Monte D , Mouton Y , Capron A , Ameisen JC . Activation-induced death by apoptosis in CD4 + T cells from human immunodeficiency virus-infected asymptomatic individuals . J Exp Med . 1992;175:331–340
  111. Meyaard L , Otto SA , Jonker RR , Mijnster MJ , Keet RP , Miedema F . Programmed death of T cells in HIV-1 infection . Science . 1992;257:217–219
  112. Lopes MF , da Veiga VF , Santos AR , Fonseca ME , DosReis GA . Activation-induced CD4 + T cell death by apoptosis in experimental Chagas' disease . J Immunol . 1995;154:744–752
  113. Franceschi C, Franceschini MG, Boschini A, Trenti T, Nuzzo C, Castellani G, et al  Phenotypic characteristics and tendency to apoptosis of peripheral blood mononuclear cells from HIV + long term non progressors . Cell Death Differ . 1997;4:815–823
  114. Cossarizza A, Mussini C, Mongiardo N, Borghi V, Sabbatini A, De Rienzo B, et al. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome . AIDS . 1997;11:19–26
  115. Ohnimus H , Heinkelein M , Jassoy C . Apoptotic cell death upon contact of CD4 + T lymphocytes with HIV glycoprotein-expressing cells is mediated by caspases but bypasses CD95 (Fas/Apo-1) and TNF receptor 1 . J Immunol . 1997;159:5246–5252
  116. Kaul M , Lipton SA . Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis . Proc Natl Acad Sci USA . 1999;96:8212–8216
  117. Ferri KF, Jacotot E, Blanco J, Este JA, Zamzami N, Susin SA, et al  Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases . J Exp Med . 2000;192:1081–1092
  118. Hashimoto F , Oyaizu N , Kalyanaraman VS , Pahwa S . Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2 . Blood . 1997;90:745–753
  119. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, et al  Apoptosis of CD8 + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4 . Nature . 1998;395:189–194
  120. Berndt C , Mopps B , Angermuller S , Gierschik P , Krammer PH . CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells . Proc Natl Acad Sci USA . 1998;95:12556–12561
  121. Fermin CD , Garry RF . Membrane alterations linked to early interactions of HIV with the cell surface . Virology . 1992;191:941–946
  122. Garg H , Blumenthal R . HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir . J Leukoc Biol . 2006;79:351–362
  123. Cossarizza A . Apoptosis and HIV infection: about molecules and genes . Curr Pharm Des . 2008;14:237–244
  124. Xu XN, Laffert B, Screaton GR, Kraft M, Wolf D, Kolanus W, et al  Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain . J Exp Med . 1999;189:1489–1496
  125. Geleziunas R , Xu W , Takeda K , Ichijo H , Greene WC . HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell . Nature . 2001;410:834–838
  126. Rasola A , Gramaglia D , Boccaccio C , Comoglio PM . Apoptosis enhancement by the HIV-1 Nef protein . J Immunol . 2001;166:81–88
  127. Sastry KJ , Marin MC , Nehete PN , McConnell K , el-Naggar AK , McDonnell TJ . Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells . Oncogene . 1996;13:487–493
  128. Bartz SR , Emerman M . Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8 . J Virol . 1999;73:1956–1963
  129. Gibellini D, Re MC, Ponti C, Vitone F, Bon I, Fabbri G, et al  HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: a potential molecular mechanism to escape TRAIL cytotoxicity . J Cell Physiol . 2005;203:547–556
  130. Li CJ , Friedman DJ , Wang C , Metelev V , Pardee AB . Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein . Science . 1995;268:429–431
  131. Creaven M, Hans F, Mutskov V, Col E, Caron C, Dimitrov S, et al. Control of the histone-acetyltransferase activity of Tip60 by the HIV-1 transactivator protein, Tat . Biochemistry . 1999;38:8826–8830
  132. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, et al  HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state . EMBO J . 1995;14:546–554
  133. Connor RI , Chen BK , Choe S , Landau NR . Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes . Virology . 1995;206:935–944
  134. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman HE, et al. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants . J Virol . 1992;66:3925–3931
  135. Levy DN , Refaeli Y , Weiner DB . Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency . J Virol . 1995;69:1243–1252
  136. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, et al. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells . J Biol Chem . 2002;277:37820–37831
  137. Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, et al  Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2 . J Exp Med . 2001;193:509–519
  138. Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, et al  The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore . J Exp Med . 2000;191:33–46

PII: S1878-3317(10)60024-1

doi:10.1016/S1878-3317(10)60024-1

Journal of Experimental & Clinical Medicine
Volume 2, Issue 4 , Pages 145-155, August 2010

Article Tools